Not every cancer is a candidate for delayed-diagnosis litigation. Some are aggressive enough that earlier diagnosis would not have meaningfully changed outcomes. Some are rare enough that no reasonable physician would have ordered the workup. The cancers that produce the bulk of viable late-diagnosis claims share a specific set of characteristics: they have established screening protocols, they have detectable early-stage symptoms, and they have well-defined standards of care that are sometimes not followed.
Four cancer types account for the majority of these matters.
Breast
Breast cancer is the most-litigated late-diagnosis cancer in the United States, in part because screening protocols are well-established and in part because the patient population is large, engaged in their own care, and willing to pursue claims when something goes wrong. The most common malpractice patterns involve misread mammograms, dismissed palpable masses, and inadequate workup of women under 40 with strong family histories.
Colorectal
Colorectal cancer claims usually involve one of three patterns: a screening colonoscopy that was either deferred too long or read inadequately; a patient presenting with symptoms (rectal bleeding, change in bowel habits, unexplained weight loss) whose workup was deferred; or a known polyp that was either incompletely removed or not adequately followed.
"The cancers that produce viable claims share a specific profile: known screening protocols, detectable early symptoms, and standards of care that are sometimes not followed."
Ovarian
Ovarian cancer is harder to diagnose early — it is sometimes called "the silent killer" — but the cases that produce litigation almost always involve documented complaints (pelvic pain, bloating, urinary changes) that were attributed to non-malignant causes without adequate workup. The standard of care has shifted in recent years to take these complaints more seriously, particularly in postmenopausal patients, and that shift has produced a meaningful volume of claims tied to physicians whose practice has not kept pace.
Prostate
Prostate cancer claims generally involve elevated PSA results that were not followed up, or were followed up inadequately, in patients who later developed metastatic disease. The standard of care is more contested in prostate than in the other three — there is genuine medical debate about overdiagnosis and overtreatment — which means cases require more careful expert development. They are also high-value when they succeed, because patients who progress to metastatic prostate cancer often have meaningful damages.
Why this matters for intake
A specialized late-diagnosis practice does not need to recognize every potential cancer-malpractice claim. It needs to recognize the four that account for most of them, and to have the screening protocols, expert relationships, and case-development infrastructure to handle those four well.
Firms that try to handle all delayed-diagnosis cancer matters as a single category tend to spread thin. Firms that specialize within these four tend to compound.